Lucy Scientific to Acquire SANA-013 Psychedelic Assets from Drug Developer Wesana Health
Transaction subject to Wesana shareholder approval and expected to close in Q2 2023SANA-013 combination of psilocybin and CBD being developed for potential...
Mental Health
NeuroStar® Advanced Therapy Receives Patient Impact Award from Life Sciences PA
Award recognizes NeuroStar for its significant contributions toward patient wellbeingMALVERN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:...
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘UPLIFT’ Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD)
Results from Planned Interim Analysis Expected Fourth Quarter 2023 Approximately 21 Million Adults in U.S. Suffer From a Major Depressive...
Field Trip Health & Wellness to Close Clinics in 5 Locations
TORONTO, March 15, 2023 (GLOBE NEWSWIRE) -- Field Trip Health & Wellness Ltd. (TSX-V: FTHW) ("Field Trip" or the “Company”)...
EMulate Therapeutics Announces the Addition of Donna Morgan Murray, Ph.D., to its Board of Directors
BELLEVUE, Wash., March 14, 2023 (GLOBE NEWSWIRE) -- EMulate Therapeutics, Inc. (“EMulate” or the “Company”) a clinical-stage company, developing digital...
VitalHub Announces Licensing of SHREWD Solution in Canada, With The Winnipeg Regional Health Authority
TORONTO, March 13, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX:VHIBF) is pleased to announce...
Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD
Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment...
Bicycle Health and Wellpath Team Up to Provide Opioid Use Disorder Treatment to Federal Bureau of Prisons
The leading virtual Opioid Use Disorder treatment provider will fill gaps in care for formerly incarcerated patients struggling with opioid...
Neuronetics Expands NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform
Company Launches a New Educational Campaign For ProvidersMALVERN, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a...
Nearly 1 in 6 workers in the US have cut back on health-related expenses due to inflation
Parents are almost twice as likely as non-parents to cut back on expenses related to their own healthCHICAGO, Feb. 23,...
BrainsWay Vice President of Medical Affairs Colleen Hanlon Honored with the 2023 International Brain Stimulation Early Career Award
BURLINGTON, Mass. and JERUSALEM, Feb. 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
One-in-five people in Canada have cut back on health-related expenses due to inflation
The latest TELUS Health Mental Health Index finds that one-third of people in Canada avoid interacting with others; financial pressure...
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
The company submitted three provisional patent applications with the United States Patent and Trademark Office to protect the novel combination compounds...
SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds
Clearmind Medicine submitted patent applications to protect the novel compoundsTel Aviv, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd....
Neuronetics Sponsors the 5th International Brain Stimulation Conference
Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced TherapyMALVERN, Pa.,...
QHSLab, Inc. Announces Representation Agreement with Healthcare Information Technology Specialists of Florida
WEST PALM BEACH, FL, Feb. 16, 2023 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on...
Michael Hilton Joins Accolade Board of Directors
Co-founder of Concur joins Board after serving as the Company’s CIOSEATTLE, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:...
DiagnaMed Prioritizes Development and Commercialization Initiatives for CERVAI™, a Brain Health AI Platform Leveraging Generative AI
CERVAI™ to be available in May 2023TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”)...
BrainsWay Announces Appointment of Hadar Levy as CEO
BURLINGTON, Mass. and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
BrainsWay Announces Appointment of Ami Boehm as New Chairman
David Zacut, M.D., Relinquishing Chairman Role Held Since Company’s Inception, to Now Serve as Board DirectorBURLINGTON, Mass. and JERUSALEM, Feb....